NCT07103486View on ClinicalTrials.gov

A Study to Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

CompletedOBSERVATIONAL
Enrollment

264

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2023

Conditions
Diffuse Large B-Cell Lymphoma
Trial Locations (1)

07936

Novartis, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT07103486 - A Study to Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Biotech Hunter | Biotech Hunter